Synapse - Thoracic Oncology

Results (3351)

Selpercatinib in RET fusion-positive non-small cell lung cancer: Final safety and efficacy, including overall survival, from the LIBRETTO-001 phase I/II trial

Journal Article

Gautschi, O.; Park, K.; Solomon, B. J.; Tomasini, P.; Loong, H. H.; De Braud, F.; Goto, K.; Peterson, P.; Barker, S.; Liming, K.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Intracranial disease control and survival among patients with KRAS-mutant lung adenocarcinoma and brain metastases treated with stereotactic radiosurgery

Journal Article

Gaeta, B.; Eichholz, J. E.; Walch, H.; Ilica, A. T.; Boe, L.; Kratochvil, L.; Yu, Y.; Gomez, D. R.; Imber, B. S.; Li, B. T.; more...
International Journal of Radiation Oncology, Biology, Physics (2025)

Fulltext@MSK | Save

Tumor immunophenotypic correlates in patients aged 80 years or older with non-small cell lung cancer and outcomes to first-line pembrolizumab in PD-L1 high (≥50%) patients

Journal Article

Barrichello, A. P. C.; Elkrief, A.; Ricciuti, B.; Ganta, T.; Marron, T. U.; Wang, X.; Lotter, W.; Lindsay, J.; Santo, V.; Cortellini, A.; more...
Clinical Lung Cancer (2025)

Fulltext@MSK | Save

Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors

Journal Article

Nykaza, I.; Murciano-Goroff, Y. R.; Desilets, A.; Harada, G.; Postow, M. A.; Callahan, M. K.; Lee, C. H.; Rudin, C. M.; Kelsen, D. P.; Stadler, Z. K.; more...
The Oncologist (2025)

Fulltext@MSK | Save

Barriers to publishing early phase clinical trials: The oncologists’ perspective

Journal Article

Lucassen, M. J. J.; Bergmann, P.; Husson, O.; Banerji, U.; Basu, B.; Melero, I.; Calvo, E.; Cassier, P. A.; Drilon, A.; Fong, P. C.; more...
The Oncologist (2025)

Fulltext@MSK | Save

Tumor-infiltrating clonal hematopoiesis

Journal Article

Pich, O.; Bernard, E.; Zagorulya, M.; Rowan, A.; Pospori, C.; Slama, R.; Huerga Encabo, H.; O'Sullivan, J.; Papazoglou, D.; Anastasiou, P.; more...
New England Journal of Medicine (2025)

Fulltext@MSK | Save

Outcomes after radiation for oligoprogressive disease sites in patients with EGFR-mutant lung cancer treated with osimertinib

Journal Article

Chen, M. F.; Jeng, M. Y.; Ma, J.; Agrawal, P.; Dunne, E.; Boe, L. A.; Kris, M. G.; Huang, J.; Veeraraghavan, H.; Gomez, D.; more...
JCO Precision Oncology (2025)

Fulltext@MSK | Save

Larotrectinib compared with real-world non-tropomyosin receptor kinase inhibitor therapies in patients with tropomyosin receptor kinase fusion cancer

Journal Article

Brose, M. S.; Westphalen, C. B.; Pan, X.; Bernard-Gauthier, V.; Kurtinecz, M.; Guo, H.; Aris, V.; Brett, N. R.; Majdi, A.; Subbiah, V.; more...
JCO Precision Oncology (2025)

Fulltext@MSK | Save

Order of treatment with ALK inhibitors and its effect on people with lung cancer in the real world: A plain language summary

Editorial

Bauman, J. R.; Liu, G.; Preeshagul, I.; Melosky, B.; Abrahami, D.; Li, B.; Thomaidou, D.; Krulewicz, S.; Rupp, M.
Future Oncology (2025)

Fulltext@MSK | Save

Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer

Journal Article

Hong, D. S.; Xu, R. H.; Shen, L.; Dierselhuis, M. P.; Orbach, D.; McDermott, R.; Italiano, A.; Tahara, M.; Bernard-Gauthier, V.; Neu, N.; more...
ESMO Open (2025)

Fulltext@MSK | Save